Business
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 /MIRA Pharmaceuticals, ...
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market.","length":186,"tagName":"p"},{"type":"text","content":"MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outperforming injected morphine in an established animal model of inflammatory pain.","length":465,"tagName":"p"},{"type":"text","content":"This study marks the first time inflammation was directly measured alongside pain in MIRA's Mira-55 program. In the Company's prior study, only pain sensitivity was evaluated, with both Mira-55 and morphine administered by injection. The new data expand those findings by demonstrating that oral administration of Mira-55 provided superior pain normalization and direct anti-inflammatory effects, whereas morphine produced only partial and indirect inflammation reduction.","length":480,"tagName":"p"},{"type":"text","content":"Study Overview and Key Findings","length":31,"tagName":"p"},{"type":"text","content":"Pain sensitivity was assessed using Von Frey Filament testing, and inflammation was quantified by paw-edema volume in the formalin-induced inflammatory pain model.","length":163,"tagName":"p"},{"type":"text","content":"Results:","length":8,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Oral Mira-55 normalized pain thresholds, fully restoring withdrawal responses to baseline and outperformed injected morphine.","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Mira-55 significantly reduced inflammation, confirming a direct CB2 receptor-mediated anti-inflammatory mechanism, while morphine showed only partial, centrally mediated effects.","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Both treatments provided pain relief, but Mira-55 delivered dual anti-inflammatory and analgesic benefits without sedation or opioid-related risks.","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":450,"olType":...